Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

HER2-positiv metastatisk brystkræft

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Orbital cysticercosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Presence of SARS-CoV-2 in semen and the impact of COVID-19 on the male reproductive system

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Behandling af mandlig infertilitet

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Kirurgisk behandling ved kvindelig infertilitet

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Dopaminergic drugs in the treatment of depression

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Mortality from cardiovascular disease in women with breast cancer - a nationwide registry study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cardiovascular disease in women with breast cancer - a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Breast cancer is the most common type of cancer among women in Denmark. In 15% of the patients with metastatic breast cancer (mBC) an overexpression of the HER2 protein on the tumour cells, amplification of the HER2-gene or both are present. HER2-positive mBC is associated with poor disease prognosis. The discovery of HER2 led to the development of HER2-targeting monoclonal antibodies significantly improving survival for patients with HER2-positive mBC as summarised in this review. The future brings even more HER2-targeting drugs, which further can contribute to the palliative treatment of HER2-postive mBC patients.

Bidragets oversatte titelTargeted treatment of HER2-positive metastatic breast cancer improves prognosis significantly
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind183
Udgave nummer26
Sider (fra-til)V12200938
ISSN0041-5782
StatusUdgivet - 28 jun. 2021

    Forskningsområder

  • Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms/drug therapy, Female, Humans, Prognosis, Receptor, ErbB-2/therapeutic use

ID: 68601334